Synthesis and activity of small molecule GPR40 agonists
摘要:
The first report on the identification and structure-activity relationships of a novel series of GPR40 agonists based on a 3(4-{[N-alkyl]amino phenyl)propanoic acid template is described. Structural modifications to the original screening hit yielded compounds with a 100-fold increase in potency at the human GPR40 receptor and pEC(50)s in the low nanomolar range. The carboxylic acid moiety is not critical for activity but typically elicits an agonistic response higher than those observed with carboxamide replacements. These compounds may prove useful in unraveling the therapeutic potential of this receptor for the treatment of Type 2 diabetes. (C) 2006 Elsevier Ltd. All rights reserved.
Chiral BINOL-based borate counterions: from cautionary tale on anion stability to enantioselective Cu-catalyzed cyclopropanation
作者:Anthony Labelle、Bruce A. Arndtsen
DOI:10.1039/d2cc05924j
日期:——
Studies on a new type of chiral BINOL-based boron counterion highlights its ability to rearrange under the reaction conditions to create a ligand that can be used in the copper-catalyzed cyclopropanation of alkenes.
Synthesis and activity of small molecule GPR40 agonists
作者:Dulce M. Garrido、David F. Corbett、Kate A. Dwornik、Aaron S. Goetz、Thomas R. Littleton、Steve C. McKeown、Wendy Y. Mills、Terrence L. Smalley、Celia P. Briscoe、Andrew J. Peat
DOI:10.1016/j.bmcl.2006.01.007
日期:2006.4
The first report on the identification and structure-activity relationships of a novel series of GPR40 agonists based on a 3(4-[N-alkyl]amino phenyl)propanoic acid template is described. Structural modifications to the original screening hit yielded compounds with a 100-fold increase in potency at the human GPR40 receptor and pEC(50)s in the low nanomolar range. The carboxylic acid moiety is not critical for activity but typically elicits an agonistic response higher than those observed with carboxamide replacements. These compounds may prove useful in unraveling the therapeutic potential of this receptor for the treatment of Type 2 diabetes. (C) 2006 Elsevier Ltd. All rights reserved.